drugset / Trial / NCT01005797
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers
Phase 1
Completed
38 enrolled
Medical University of South Carolina
Novartis Pharmaceuticals · collab
RandomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if a new investigational drug called Panobinostat is safe, tolerable and to obtain an initial assessment of efficacy, when given in combination with Sorafenib for the treatment of certain types of lung cancer, kidney cancer and soft tissue sarcoma.
Timeline
- Start
- 2009-11
- Primary completion
- 2014-03
- Completion
- 2017-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panobinostat | Small molecule | 15 mg | — |
| Subject | Sorafenib | Small molecule | 400 mg | — |